RT Journal Article
SR Electronic
T1 Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-Negative Case-Control Design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268726
DO 10.1101/2022.01.06.22268726
A1 Reynolds, Matthew W
A1 Secora, Alex
A1 Joules, Alice
A1 Albert, Lisa
A1 Brinkley, Emma
A1 Kwon, Tom
A1 Mack, Christina
A1 Toovey, Stephen
A1 Dreyer, Nancy A.
YR 2022
UL http://medrxiv.org/content/early/2022/01/06/2022.01.06.22268726.abstract
AB It is important to assess the extent to which the real-world effectiveness of marketed vaccines is consistent with that observed in the clinical trials, and to characterize how well vaccines prevent COVID-19 symptoms. We conducted a modified test-negative design (TND) to evaluate the RW effectiveness of three COVID-19 vaccines by leveraging data from an on-going, US community-based registry. Vaccine effectiveness was examined in two ways: considering cases who (1) tested positive for COVID-19 (695 cases, 1,786 controls) and who (2) tested positive with at least one moderate/severe COVID-19 symptom (165 cases, 2,316 controls). Any vaccination (full or partial) was associated with a 95% reduction in the odds of having a positive COVID-19 test [adjusted odds ratio (aOR) = 0.05 (95% confidence interval (CI): 0.04, 0.06)]. Full vaccination was associated with an aOR of 0.03 (95% CI: 0.03, 0.05) while partial vaccination had an aOR of 0.08 (95% CI: 0.06, 0.12). Any vaccination was associated with a 71% reduction in the odds of testing positive and having at least one moderate/severe symptom (aOR=0.29 (95% CI: 0.20, 0.40)). High effectiveness was observed across all three vaccine manufacturers both for prevention of positive COVID-19 test results and prevention of moderate/severe COVID-19 symptoms.Clinicaltrials.gov NCT04368065Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by a contract with the US Food and Drug Administration. The bulk of the funding was provided by IQVIAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Advarra gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to data privacy and security regulations the researchers are not able to share participant level data.